Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Follow-Up Questions
Advicenne SA 的 CEO 是誰？
Mr. Didier Laurens 是 Advicenne SA 的 Chief Executive Officer，自 2021 加入公司。
ADVVF 股票的價格表現如何？
ADVVF 的當前價格為 $0，在上個交易日 decreased 了 0%。
Advicenne SA 的主要業務主題或行業是什麼？
Advicenne SA 屬於 Pharmaceuticals 行業，該板塊是 Health Care
